Loading...
Loading...
GSK plc
GSK plc. Spoken Alpha tracks GSK's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks GSK's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GSK.
curl https://api.spokenalpha.com/v1/companies/GSK| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $6.29 | $4.30 | +46.3% | -5.8% | -8.8% |
| Q4 FY2026 | $5.90 | $4.33 | +36.3% | -7.7% | -9.0% |
| Q3 FY2026 | $5.66 | $4.24 | +33.6% | +1.1% | -1.0% |
| Q2 FY2026 | $6.09 | $4.34 | +40.4% | -3.5% | -6.1% |
| Q1 FY2025 | $6.11 | $4.27 | +43.0% | -9.5% | -6.9% |
| Q4 FY2025 | $6.32 | $4.49 | +40.8% | +0.9% | -2.1% |
| Q3 FY2025 | $6.17 | $4.54 | +35.8% | -3.4% | -1.1% |
| Q2 FY2025 | $5.93 | $4.40 | +34.7% | +2.0% | +0.9% |
| Q1 FY2024 | $5.99 | $4.51 | +32.8% | -5.2% | -4.2% |
| Q4 FY2024 | $6.24 | $4.45 | +40.3% | -2.2% | -5.0% |